The global in vivo preclinical brain imaging devices market is expected to reach USD 1,124,983.68 thousand by 2030 from USD 714,350.31 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030.
Market Segmentation
Global In Vivo Preclinical Brain Imaging Devices Market, By Imaging Modality Type (MRI, PET/SPECT, CT, Optical Miniscopes, 2Photon Confocal, US, NIR Fluorescence, OCT, Bioluminescence, and Others), Application (Drug Discovery, Disease Characterization, and Toxicology), Therapeutic Area (Alzheimer's Disease, Parkinson's Disease, Oncology, and Other Therapeutic Areas), Biological Variable (BOLD, Oxygenation, Blood Flow, Microvessels, Neuronal Activity, and Soft Tissue), Temporal Format of Use (Under an Hour, Many Hours, and Longitudinal) End User (Pharma-Inhouse, CRO, Academia, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Switzerland, Netherlands, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.
Overview of Global In Vivo Preclinical Brain Imaging Devices Market Dynamics
- Driver
- Rising prevalence of neurological disorder
- Restraint
- Ethical and regulatory consideration
- Opportunity
- Rising research and development activities
Market Players
The key market players operating in the global invivo preclinical brain imaging devices market are:
- Bruker
- PerkinElmer Inc.
- FUJIFILM Corporation
- Miltenyi Biotec
- Charles River Laboratories.
- Hologic, Inc.
- LI-COR, Inc.
- MILabs B.V.
- TriFoil Imaging
- Berthold Technologies GmbH & Co.KG
- A14R
- Aspect Imaging Ltd.
- Cubresa Inc.
- Mediso Ltd.
- MR Solutions
- Spectrum Instruments Imaging
TABLE OF CONTENTS
1 INTRODUCTION 25
- 1.1 OBJECTIVES OF THE STUDY 25
- 1.2 MARKET DEFINITION 25
- 1.3 OVERVIEW OF THE GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET 25
- 1.4 CURRENCY AND PRICING 26
- 1.5 LIMITATIONS 27
- 1.6 MARKETS COVERED 27
2 MARKET SEGMENTATION 29
- 2.1 MARKETS COVERED 29
- 2.2 GEOGRAPHICAL SCOPE 30
- 2.3 YEARS CONSIDERED FOR THE STUDY 31
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
- 2.6 MULTIVARIATE MODELLING 36
- 2.7 IMAGING MODALITY TYPE SEGMENT LIFELINE CURVE 36
- 2.8 MARKET END USER COVERAGE GRID 37
- 2.9 DBMR MARKET POSITION GRID 38
- 2.10 VENDOR SHARE ANALYSIS 40
- 2.11 SECONDARY SOURCES 41
- 2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 45
- 4.1 PESTEL ANALYSIS 48
- 4.2 PORTR'S FIVE FORCES 49
5 REGULATORY FRAMEWORK 50
- 5.1 REGULATORY SCENARIO IN U.S. 50
- 5.2 REGULATORY SCENARIO IN AUSTRALIA 50
- 5.3 REGULATORY SCENARIO IN EUROPE 51
- 5.4 REGULATORY SCENARIO IN SOUTH AFRICA 51
- 5.5 REGULATORY SCENARIO IN BRAZIL 51
6 MARKET OVERVIEW 52
- 6.1 DRIVERS 54
- 6.1.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS 54
- 6.1.2 ADVANCEMENTS IN IMAGING TECHNIQUES USED IN BRAIN IMAGING 54
- 6.1.3 INCREASING ADOPTION OF IN-VIVO IMAGING SYSTEMS 55
- 6.2 RESTRAINTS 55
- 6.2.1 ETHICAL AND REGULATORY CONSIDERATIONS 55
- 6.2.2 HIGH COST ASSOCIATED WITH BRAIN IMAGING EQUIPMENT 55
- 6.3 OPPORTUNITIES 56
- 6.3.1 RISING STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 56
- 6.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 56
- 6.4 CHALLENGES 57
- 6.4.1 LACK OF SKILLED PROFESSIONALS DUE TO TECHNOLOGY ADVANCEMENT 57
- 6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES 58
7 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY IMAGING MODALITY TYPE 59
- 7.1 OVERVIEW 60
- 7.2 MRI 61
- 7.3 PET/SPECT 62
- 7.4 CT 62
- 7.5 OPTICAL MINISCOPES 63
- 7.6 2 PHOTON CONFOCAL 63
- 7.7 US 64
- 7.8 NIR FLUORESCENCE 64
- 7.9 OCT 65
- 7.10 BIOLUMINESCENCE 65
- 7.11 OTHERS 66
8 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY APPLICATION 67
- 8.1 OVERVIEW 68
- 8.2 DRUG DISCOVERY 69
- 8.2.1 PRECLINICAL STUDIES 70
- 8.2.2 EARLY DRUG DISCOVERY 70
- 8.2.3 CLINICAL DEVELOPMENT 70
- 8.2.4 POST MARKET MONITORING 70
- 8.2.5 DATA REVIEW 70
- 8.3 DISEASE CHARACTERIZATION 70
- 8.4 TOXICOLOGY 71
9 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY THERAPEUTIC AREA 72
- 9.1 OVERVIEW 73
- 9.2 ALZHEIMER'S DISEASE 74
- 9.3 PARKINSON'S DISEASE 75
- 9.4 ONCOLOGY 75
- 9.5 OTHER THERAPEUTIC AREAS 76
10 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY BIOLOGICAL VARIABLE 77
- 10.1 OVERVIEW 78
- 10.2 BOLD 79
- 10.3 OXYGENATION 80
- 10.4 BLOOD FLOW 80
- 10.5 MICROVESSELS 81
- 10.6 NEURONAL ACTIVITY 81
- 10.7 SOFT TISSUE 82
11 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY TEMPORAL FORMAT OF USE 83
- 11.1 OVERVIEW 84
- 11.2 UNDER AN HOUR 85
- 11.3 MANY HOURS 86
- 11.4 LONGITUDINAL 86
12 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY END USER 87
- 12.1 OVERVIEW 88
- 12.2 PHARMA-INHOUSE 89
- 12.3 CRO 90
- 12.4 ACADEMIA 90
- 12.5 OTHERS 91
13 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, BY REGION 92
- 13.1 OVERVIEW 93
- 13.2 NORTH AMERICA 96
- 13.3 EUROPE 105
- 13.4 ASIA-PACIFIC 129
- 13.5 SOUTH AMERICA 153
- 13.6 MIDDLE EAST AND AFRICA 161
14 GLOBAL IN VIVO PRECLINICAL BRAIN IMAGING DEVICES MARKET, COMPANY LANDSCAPE 175
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 175
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 176
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 177
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 178
15 SWOT ANALYSIS 179
16 COMPANY PROFILE 180
- 16.1 BRUKER 180
- 16.1.1 COMPANY SNAPSHOT 180
- 16.1.2 REVENUE ANALYSIS 180
- 16.1.3 COMPANY SHARE ANALYSIS 181
- 16.1.4 PRODUCT PORTFOLIO 181
- 16.1.5 RECENT DEVELOPMENT 181
- 16.2 PERKINELMER INC. 182
- 16.2.1 COMPANY SNAPSHOT 182
- 16.2.2 REVENUE ANALYSIS 182
- 16.2.3 COMPANY SHARE ANALYSIS 183
- 16.2.4 PRODUCT PORTFOLIO 183
- 16.2.5 RECENT DEVELOPMENT 183
- 16.3 FUJIFILM CORPORATION 184
- 16.3.1 COMPANY SNAPSHOT 184
- 16.3.2 REVENUE ANALYSIS 184
- 16.3.3 COMPANY SHARE ANALYSIS 185
- 16.3.4 PRODUCT PORTFOLIO 185
- 16.3.5 RECENT DEVELOPMENT 185
- 16.4 MILTENYI BIOTEC 186
- 16.4.1 COMPANY SNAPSHOT 186
- 16.4.2 COMPANY SHARE ANALYSIS 186
- 16.4.3 PRODUCT PORTFOLIO 187
- 16.4.4 RECENT DEVELOPMENT 187
- 16.5 CHARLES RIVER LABORATORIES. 188
- 16.5.1 COMPANY SNAPSHOT 188
- 16.5.2 REVENUE ANALYSIS 188
- 16.5.3 COMPANY SHARE ANALYSIS 189
- 16.5.4 PRODUCT PORTFOLIO 189
- 16.5.5 RECENT DEVELOPMENT 189
- 16.6 AI4R 190
- 16.6.1 COMPANY SNAPSHOT 190
- 16.6.2 PRODUCT PORTFOLIO 190
- 16.6.3 RECENT DEVELOPMENT 190
- 16.7 ASPECT IMAGING LTD. 191
- 16.7.1 COMPANY SNAPSHOT 191
- 16.7.2 PRODUCT PORTFOLIO 191
- 16.7.3 RECENT DEVELOPMENT 191
- 16.8 BERTHOLD TECHNOLOGIES GMBH & CO.KG 192
- 16.8.1 COMPANY SNAPSHOT 192
- 16.8.2 PRODUCT PORTFOLIO 192
- 16.8.3 RECENT DEVELOPMENT 192
- 16.9 CUBRESA INC. 193
- 16.9.1 COMPANY SNAPSHOT 193
- 16.9.2 PRODUCT PORTFOLIO 193
- 16.9.3 RECENT DEVELOPMENT 193
- 16.10 HOLOGIC, INC. 194
- 16.10.1 COMPANY SNAPSHOT 194
- 16.10.2 REVENUE ANALYSIS 194
- 16.10.3 PRODUCT PORTFOLIO 195
- 16.10.4 RECENT DEVELOPMENT 195
- 16.11 LI-COR, INC. 196
- 16.11.1 COMPANY SNAPSHOT 196
- 16.11.2 PRODUCT PORTFOLIO 196
- 16.11.3 RECENT DEVELOPMENT 196
- 16.12 MEDISO LTD. 197
- 16.12.1 COMPANY SNAPSHOT 197
- 16.12.2 PRODUCT PORTFOLIO 197
- 16.12.3 RECENT DEVELOPMENT 197
- 16.13 MILABS B.V. 198
- 16.13.1 COMPANY SNAPSHOT 198
- 16.13.2 PRODUCT PORTFOLIO 198
- 16.13.3 RECENT DEVELOPMENT 198
- 16.14 MR SOLUTIONS 199
- 16.14.1 COMPANY SNAPSHOT 199
- 16.14.2 PRODUCT PORTFOLIO 199
- 16.14.3 RECENT DEVELOPMENT 199
- 16.15 SPECTRAL INSTRUMENTS IMAGING 200
- 16.15.1 COMPANY SNAPSHOT 200
- 16.15.2 PRODUCT PORTFOLIO 200
- 16.15.3 RECENT DEVELOPMENT 200
- 16.16 TRIFOIL IMAGING 201
- 16.16.1 COMPANY SNAPSHOT 201
- 16.16.2 PRODUCT PORTFOLIO 201
- 16.16.3 RECENT DEVELOPMENT 201
17 QUESTIONNAIRE 202
18 RELATED REPORTS 205